ArticleScientific reports2025
Development and validation of a CT-measured body composition radiomics model for prognostic assessment in resected pancreatic adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Abdominal CT findings on the day of death in patients with solid organ malignancies.Abdominal radiology (New York) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis due to high post-resection recurrence, yet current prognostic tools inadequately capture systemic tumor-host interactions. This study developed and validated a novel CT-based body composition radiomics model for predicting recurrence-free survival (RFS) in 191 PDAC patients undergoing curative resection. Using a temporal validation design (training cohort: 2019-2022, n = 142; validation cohort: 2016-2018, n = 49), we extracted 1,688 radiomics features from adipose and muscle tissues at the L3 vertebral level. Following a standardized feature selection protocol (variance filtering, correlation reduction, and Cox regression), we constructed fat- and muscle-specific radiomics scores, combining them into a unified risk stratification system. The combined model effectively identified high-risk patients with significantly reduced RFS (HR = 6.455, p < 0.001), achieving consistent performance across cohorts (C-index: 0.71 training, 0.69 validation). This approach quantifies metabolic alterations in body composition, providing a clinically actionable tool to guide personalized therapy decisions-including intensified neoadjuvant regimens for high-risk patients or standard surveillance for low-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.